AU2022390803A1 - Compounds for use in treating gastric cancer - Google Patents
Compounds for use in treating gastric cancer Download PDFInfo
- Publication number
- AU2022390803A1 AU2022390803A1 AU2022390803A AU2022390803A AU2022390803A1 AU 2022390803 A1 AU2022390803 A1 AU 2022390803A1 AU 2022390803 A AU2022390803 A AU 2022390803A AU 2022390803 A AU2022390803 A AU 2022390803A AU 2022390803 A1 AU2022390803 A1 AU 2022390803A1
- Authority
- AU
- Australia
- Prior art keywords
- formula
- pharmaceutically acceptable
- halo
- alkyl
- acceptable salt
- Prior art date
- Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
- Pending
Links
Classifications
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/33—Heterocyclic compounds
- A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
- A61K31/41—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having five-membered rings with two or more ring hetero atoms, at least one of which being nitrogen, e.g. tetrazole
- A61K31/4196—1,2,4-Triazoles
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P35/00—Antineoplastic agents
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P35/00—Antineoplastic agents
- A61P35/04—Antineoplastic agents specific for metastasis
Landscapes
- Health & Medical Sciences (AREA)
- Public Health (AREA)
- General Health & Medical Sciences (AREA)
- Veterinary Medicine (AREA)
- Pharmacology & Pharmacy (AREA)
- Medicinal Chemistry (AREA)
- Animal Behavior & Ethology (AREA)
- Chemical & Material Sciences (AREA)
- Life Sciences & Earth Sciences (AREA)
- Organic Chemistry (AREA)
- Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
- General Chemical & Material Sciences (AREA)
- Chemical Kinetics & Catalysis (AREA)
- Oncology (AREA)
- Epidemiology (AREA)
- Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
Applications Claiming Priority (3)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| US202163280540P | 2021-11-17 | 2021-11-17 | |
| US63/280,540 | 2021-11-17 | ||
| PCT/US2022/050289 WO2023091590A1 (en) | 2021-11-17 | 2022-11-17 | Compounds for use in treating gastric cancer |
Publications (1)
| Publication Number | Publication Date |
|---|---|
| AU2022390803A1 true AU2022390803A1 (en) | 2024-06-20 |
Family
ID=84887956
Family Applications (1)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| AU2022390803A Pending AU2022390803A1 (en) | 2021-11-17 | 2022-11-17 | Compounds for use in treating gastric cancer |
Country Status (8)
| Country | Link |
|---|---|
| US (1) | US20250017906A1 (cg-RX-API-DMAC7.html) |
| EP (1) | EP4433051A1 (cg-RX-API-DMAC7.html) |
| JP (1) | JP2024543111A (cg-RX-API-DMAC7.html) |
| KR (1) | KR20240149878A (cg-RX-API-DMAC7.html) |
| CN (1) | CN118488837A (cg-RX-API-DMAC7.html) |
| AU (1) | AU2022390803A1 (cg-RX-API-DMAC7.html) |
| CA (1) | CA3238430A1 (cg-RX-API-DMAC7.html) |
| WO (1) | WO2023091590A1 (cg-RX-API-DMAC7.html) |
Families Citing this family (2)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| WO2021138540A1 (en) * | 2020-01-03 | 2021-07-08 | Berg Llc | Polycyclic amides as ube2k modulators for treating cancer |
| US20240342138A1 (en) * | 2023-04-13 | 2024-10-17 | Bpgbio, Inc. | Microtubule targeting agents |
Family Cites Families (3)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| WO2017210694A1 (en) * | 2016-06-03 | 2017-12-07 | An2H Discovery Limited | Triazole benzamide derivatives and the compositions and methods of treatment regarding the same |
| BR112021004417A2 (pt) * | 2018-09-10 | 2021-06-01 | Berg Llc | métodos para tratar câncer pela inibição de enzima e2 k de conjugação de ubiquitina (ube2k) |
| WO2021138540A1 (en) * | 2020-01-03 | 2021-07-08 | Berg Llc | Polycyclic amides as ube2k modulators for treating cancer |
-
2022
- 2022-11-17 CN CN202280082007.5A patent/CN118488837A/zh active Pending
- 2022-11-17 JP JP2024529934A patent/JP2024543111A/ja active Pending
- 2022-11-17 EP EP22839548.9A patent/EP4433051A1/en active Pending
- 2022-11-17 WO PCT/US2022/050289 patent/WO2023091590A1/en not_active Ceased
- 2022-11-17 AU AU2022390803A patent/AU2022390803A1/en active Pending
- 2022-11-17 CA CA3238430A patent/CA3238430A1/en active Pending
- 2022-11-17 KR KR1020247020095A patent/KR20240149878A/ko active Pending
- 2022-11-17 US US18/711,570 patent/US20250017906A1/en active Pending
Also Published As
| Publication number | Publication date |
|---|---|
| CA3238430A1 (en) | 2023-05-25 |
| US20250017906A1 (en) | 2025-01-16 |
| WO2023091590A1 (en) | 2023-05-25 |
| CN118488837A (zh) | 2024-08-13 |
| EP4433051A1 (en) | 2024-09-25 |
| JP2024543111A (ja) | 2024-11-19 |
| KR20240149878A (ko) | 2024-10-15 |
Similar Documents
| Publication | Publication Date | Title |
|---|---|---|
| AU2009279944B2 (en) | Dihydropyridophthalazinone inhibitors of poly(ADP-ribose)polymerase (PARP) | |
| TWI632911B (zh) | 腫瘤溶解症候群之治療劑及預防劑 | |
| TWI810185B (zh) | 一種ezh2抑制劑與btk抑制劑聯合在製備治療腫瘤的藥物中的用途 | |
| WO2023091590A1 (en) | Compounds for use in treating gastric cancer | |
| TW201919612A (zh) | 包含帕博西尼(palbociclib)及6-(2,4-二氯苯基)-5-[4-[(3s)-1-(3-氟丙基)吡咯啶-3-基]氧基苯基]-8,9-二氫-7h-苯并[7]輪烯-2-甲酸的組合 | |
| KR20130079429A (ko) | 헤테로시클릭 설폰 mglur4 알로스테릭 강화제, 조성물 및 신경 기능이상을 치료하는 방법 | |
| JP2022527398A5 (cg-RX-API-DMAC7.html) | ||
| TW201306842A (zh) | 使用pi3k/mtor吡啶並嘧啶酮抑制劑及苯達莫司汀及/或利妥昔單抗治療惡性血液疾病之組合療法 | |
| JP2015512398A (ja) | Pfkfb2阻害剤および抗癌治療法としての使用方法 | |
| WO2018233620A1 (zh) | SERD与CDK4/6抑制剂、PI3K/mTOR通路抑制剂的用途 | |
| CN103841976A (zh) | Akt和mek抑制剂化合物的组合及其使用方法 | |
| JP2024069223A5 (cg-RX-API-DMAC7.html) | ||
| US6537991B1 (en) | Method of treating a peripheral neuropathic pain | |
| CA3205023A1 (en) | Pyrido[2,3-d]imidazole derivatives and their use as inhibitors of itk for the teatment of skin disease | |
| KR20220035143A (ko) | 사이클릭 디옥시리보뉴클레오티드 화합물 | |
| AU2014296145A1 (en) | Compound and methods for treating long QT syndrome | |
| JP2024523558A5 (cg-RX-API-DMAC7.html) | ||
| JP2024505515A5 (cg-RX-API-DMAC7.html) | ||
| AU2024229823B2 (en) | Compositions and methods for making and using small molecules for the treatment of health conditions | |
| JP2010526073A (ja) | 癌または前癌性症状およびその他の症状の治療のためのジヒドロピリジン誘導体 | |
| WO2025202900A1 (en) | Cdk4 inhibitors for use in the treatment of mantle cell lymphoma | |
| CN113966329B (zh) | 作为pdl1检查点抑制剂的杂环免疫调节剂 | |
| US20240239760A1 (en) | Pparg inverse agonists and uses thereof | |
| JP2022532194A (ja) | Pi3k阻害剤の結晶多形及びその製造方法 | |
| WO2024138160A1 (en) | Pparg inverse agonists and uses thereof |